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postmenopausal women attending a clinic in Western New York, to undergo mammo-
graphic assessment. Eligible participants included women without cancer, no recent 
use of hormone-replacement therapy, and no history of breast augmentation or breast 
reduction surgery. A self-administered questionnaire was used to obtain information 
on demographics, anthropometry, and breast cancer risk factors. Percent density (PD) 
was measured using computer-assisted assessment of mammographic films. General 
linear models were used to test for differences in PD by smoking variables while 
adjusting for selected covariates (age, body mass index, age at first live birth, age at 
menopause, use of hormone therapy, level of education, and family history of breast 
cancer). Results: Study participants (n= 229) included 125 never-smokers, 87 former 
smokers, and 17 current smokers. Current smokers had a lower mean percent density 
(SE) compared to non-current smokers and former smokers (29.6 (5.1) vs. 34.8 (3.9) 
and 37.5 (4.1) p= 0.09). Among ever smokers, age at smoking initiation was inversely 
associated with percent density (P= 0.002). No significant associations were observed 
for the other smoking variables. ConClusions: Younger age at smoking initiation is 
associated with higher PD while current smoking is associated with lower PD. These 
findings suggest that smoking may have differential effects on risk of postmenopau-
sal breast cancer depending on the timing of exposure.
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objeCtives: Surgery is a standard modality in the modern management of solid 
tumors. Unfortunately, some patients will experience unplanned readmissions and 
ED visits following their operation. Emerging trends in health reform have intro-
duced new financial detriments to hospital reencounters in addition to the negative 
impact on quality of care. Our objective was to develop an electronic approach to 
assessing unplanned hospital reencounters following common cancer operations 
in order to guide decision-making aimed improving value in our patient popula-
tion. Methods: The target population for this study was adult cancer patients 
undergoing mastectomy and colectomy operations for cancer. Data were abstracted 
using an Electronic Data Warehouse (EDW) to determine 30-day emergency depart-
ment visits and hospital readmissions following the selected cancer operations. 
The secondary outcome measure was cost of care for patients returning to the 
hospital within 30-days. Results: Among 105 patients undergoing selected breast 
and colon cancer operations from January 1, 2012 to December 31, 2012 the hospital 
reencounter rate was 11.9%. Wound-related complications were responsible for 
73% of these hospital reencounters. Total costs (direct and indirect) for hospital 
reencounters were $210,722.76. ConClusions: Unplanned hospital readmissions 
and emergency department visits following cancer surgery largely result from post-
operative complications. These unplanned reencounters are a costly source of poor 
quality care. Patient-centered, disease-specific efforts to reduce unplanned hospital 
reencounters have the potential to significantly increase quality while decreas-
ing costs. Using data for decision-making in quality improvement is important for 
achieving value in patient care.
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objeCtives: Bevacizumab is a recombinant, humanized monoclonal antibody that 
hinders the proliferation of new blood vessels in malignant cells. It plays an impor-
tant role in the management of colorectal cancer; however, there is concern about its 
association with the development of thrombosis. The purpose of current study was 
to address the overall risk of thrombotic events in colorectal cancer patients treated 
with Bevacizumab-based chemotherapy as well as the risk of both arterial and 
venous thrombotic events separately. Methods: PUBMED/MEDLINE database was 
searched to find relevant clinical trials that published in English language between 
the periods January 1st, 2003 and December 31st 2013. Only randomized control tri-
als (RCTs) that compared non-Bevacizumab to Bevacizumab-based chemotherapy 
regimen for the treatment of colorectal cancer and reported thrombotic events 
were included. The relative risk (RR) with 95% confidence intervals of thrombotic 
events was calculated. Because between-study heterogeneity was insignificant, 
the fixed effect model was used to calculate the estimated effect sizes. Results: 
There were a total of 22 randomized clinical trials that have met our search criteria 
with a total of 12,852 patients used for safety analysis calculations. Based on our 
findings, there is a significant risk of overall thrombotic events in Bevacizumab vs 
control treated group RR = 1.315 (95% CI 1.165-1.483, P = < .0001). In terms of venous 
thrombosis, there is a significant risk in Bevacizumab treated patients with a RR 
= 1.256 (95% CI 1.097-1.43, P = 0.0019) compared to control. Finally, a higher risk of 
arterial thrombosis in patients used Bevacizumab vs control treated groups RR = 
1.635 (95% CI 1.1802.264, P = 0.0065). Sensitivity analyses showed no significant dif-
ferences. ConClusions: Bevacizumab-based chemotherapy is significantly asso-
ciated with the development of thrombotic events either as venous or as arterial 
thrombosis. Health care providers are encouraged to consider thrombosis prophy-
laxis regimen and periodically monitoring their patients.
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objeCtives: To determine if cardiovascular (CV) drugs are associated with an 
increased risk of colon cancer (CC) & if the risk for any individual agent differs from 
inhibitors or to ARBs experienced a significantly decreased all-cause mortality risk 
as compared to those who were not (HR= 0.90, 95% CI: 0.85 – 0.95 and HR= 0.92, 95% 
CI: 0.86 – 0.98, respectively). ConClusions: Our population-based study showed 
that the use of ACE inhibitors and ARBs was associated with reduced overall mortal-
ity in patients with pancreatic cancer. Although modest, such benefits may be of 
great clinical importance because of the low overall survival rate seen in patients 
with pancreatic cancer and the relative safety of ACE inhibitors and ARBs. These 
relationships should be further examined in other populations using similar mod-
eling techniques.
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objeCtives: SREs are common in men with mPC and some individuals experi-
ence multiple SREs. We estimated the burden and timing of SREs in elderly men 
diagnosed with mPC. Methods: We analyzed elderly men diagnosed with mPC 
between 2000-2009 in the SEER-Medicare datasets and followed through 12/31/2010 
or until lost to follow-up. Post-diagnosis SREs were identified using claims that 
indicated spinal cord compression (SCC), pathologic fracture (PF), surgery to bone 
(SB), or radiation (RAD, potentially suggestive of bone palliative radiation). Results: 
Among 8,997 mPC men with a median follow up of 18 months, 4,176 (47.7%) expe-
rienced at least one SRE. The median (mean) time from mPC diagnosis to first SRE 
was 154 (335) days. The median times from mPC diagnosis to first RAD, PF, SCC, or 
SB were 204, 96, 44, or 85 days, respectively. Of the 4,176 men who had at least one 
SRE, 2,619 (62.7%) had a subsequent SRE and 1,442 (35%) had a subsequent SRE of 
a different type. The median (mean) time from first SRE to any second SRE was 23 
(108) days, while it was 21 (177) days from first SRE to second SRE of a different type. 
Subsequent SRE patterns varied considerably depending on the first SRE type. The 
majority of patients who experienced a PF or SCC first quickly had SB within 2 days 
or RAD within a month. ConClusions: The median time from first SRE to second 
SRE was considerably shorter than the median time from mPC diagnosis to first SRE, 
suggesting that once patients have had an SRE, it is quicker to develop subsequent 
SREs. Individuals who had a PF or SCC as a first SRE received RAD or SB within one 
month. These findings provide additional data to guide monitoring and prevention 
of SREs in the elderly mPC population.
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objeCtives: Advanced (stage IIIB/C and IV) melanoma is an aggressive, deadly 
disease and has a high detrimental impact on patients and society, primarily due 
to premature death. Understanding the burden of advanced melanoma is therefore 
important for health policy and allocating appropriate health care resources to 
treatment. There is limited data available specifically related to burden of advanced 
melanoma on patients. The aim of this study was to estimate years of life lost in 
patients with advanced melanoma in 12 countries. Methods: Population growth 
and life expectancy were estimated from OECD data and country-specific life tables, 
respectively. Incidence and mortality data for advanced melanoma were collected 
from local cancer registries and GLOBOCAN 2008. Population growth and incidence 
rates by stage of disease were used to estimate the growth in the size of the mela-
noma patient population and new cases of advanced melanoma in 2014, respec-
tively. Melanoma-specific mortality rates were used to estimate the number of 
patients surviving from previous years, to calculate prevalence, mortality and age at 
death for patients with advanced melanoma. Age and sex-adjusted life tables were 
subsequently used to estimate years of life lost for these patients. Results: Years 
of life lost due to advanced melanoma per patient were as follows: Australia (men: 
19.9 years, women: 22.7 years); Brazil (16.3, 19.8); Canada (19.4, 22.3); France (18.8, 
23.1); Germany (18.3, 20.8); Italy (19.3, 22.7); Mexico (17.2, 19.0); the Netherlands (18.5, 
21.5); Spain (19.2, 23.1); Sweden (19.4, 22.0); UK (18.7, 21.2); US (17.9, 20.6). Country 
differences were primarily driven by melanoma mortality rates and disease-free 
life expectancy. ConClusions: This study estimated the years of life lost due to 
advanced melanoma in 12 countries and found variations across countries and vari-
ations between sexes; however, the burden of advanced melanoma is substantial 
in all of the countries.
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objeCtives: Tobacco contains numerous carcinogens, including several known to 
cause mammary tumors in animal models. Our study aimed to investigate whether 
mammographic density (MD), a recognized risk factor associated with breast cancer, 
is influenced by smoking history. Methods: This was a cross-sectional study of 
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objeCtives: To determine if the starting time of chemotherapy influences on ill-
ness-free survival and general survival in a cohort of Mexican patients with breast 
cancer. Methods: A prospective study over 5 years was performed on 88 women 
with breast cancer from the National Medical Centre “La Raza” of the Mexican 
Institute of Social Security (IMSS) with the following characteristics: stages I-III and 
positive criteria for adjuvant chemotherapy. The time range for the chemotherapy 
administration was 0 to 2, 3 and > 4 months. The analysis was performed regarding 
chemotherapy administration time interval using a Kaplan-Meier estimator. The 
Cox model was adjusted to see the relationships between the global survival and the 
oestrogen and progesterone hormone receptor variables and HER2/NEU as well as 
their basal characteristics. Results: For both IFS and GS there was a significantly 
statistical difference on the survival distributions related to starting time of chemo-
therapy which had a higher probability from a range of 0 to 2 months (median GS 
59 months median IFS 49 months; p-value< 0.001). Regarding general survival, the 
hormonal receptors for oestrogen, progesterone and HER2/NEU do not influence 
on the Cox model (p-value= 0.137, 0.823, 0.524 respectively); for the Cox model with 
basal characteristics, age, pathological state and time interval between surgery and 
chemotherapy influenced significantly on GS (p-value< 0.05) ConClusions: The 
probability of survival for IFS and GS improve when chemotherapy is administered 
within the first 2 months after surgery. Also, there was a greater risk for GS when 
time interval between surgery and chemotherapy was prolonged. This delay for the 
starting time of chemotherapy will impact without a doubt in the health systems´ 
economy, generating more expenses for attention.
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objeCtives: To investigate treatment and survival patterns among ALK+ non-
small cell lung cancer (NSCLC) patients following discontinuation with crizotinib 
monotherapy. Methods: Medical charts for ALK+ NSCLC patients who discon-
tinued treatment with crizotinib monotherapy were retrospectively reviewed and 
abstracted by a panel of 27 oncologists. Patients were randomly selected by phy-
sicians among their eligible crizotinib-treated patients. Results: A total of 119 
ALK+NSCLC patients who received crizotinib monotherapy and changed regimen 
prior to death or last follow-up were analyzed. At primary NSCLC diagnosis, patients 
averaged 65 years old and 56% (n= 66) were male. A majority of them received first-
line crizotinib monotherapy (60% first-line; 33% second-line), and median crizotinib 
treatment duration for all 119 patients was 141 days (IQR: 92-209). Before chang-
ing crizotinib monotherapy regimen, 38 (32%) patients were diagnosed with brain 
metastases. A total of 102 (86%) patients had progressed while on crizotinib mono-
therapy after a median time of 140 days (IQR: 88-219) post crizotinib initiation, and 
changed regimen after a median of 1 day (IQR: 1-3) post progression. After discon-
tinuing crizotinib, 50 (42%) patients did not receive antineoplastic therapy. Among 
the 69 patients (58%) who received treatment, 37 (54%) received chemotherapy, 15 
(22%) radiation therapy without chemotherapy, 13 (19%) a targeted therapy, and 
4 (6%) were enrolled in a clinical trial. Among all patients, median survival post 
crizotinib monotherapy was 61 days. The median survival was 180 days for the 69 
patients who received treatment post crizotinib monotherapy and 17 days for those 
who did not receive antineoplastic therapy. The median survival was 44 days for 
the 38 patients with brain metastases. ConClusions: There is significant unmet 
need among patients progressing on crizotinib. In this retrospective study, ALK+ 
NSCLC patients were found to have an overall survival of 61 days post crizotinib 
monotherapy; additional studies are necessary to understand clinical outcomes 
among patients progressing on crizotinib.
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objeCtives: Lung cancer is the leading cause of cancer related death in Canada. 
Lobectomy is the most common form of treatment for early stage lung cancer and 
can be performed using an open approach with a thoracotomy incision or as a 
minimally-invasive procedure using Video-Assisted Thoracic Surgery (VATS). Several 
recent studies have demonstrated that open and VATS lobectomies achieve onoco-
logically equivalent outcomes, which has lead to rising popularity for VATS. In the 
Canadian health care environment hospitals are faced with increasingly restrictive 
budgets, creating a critical need to demonstrate the cost-effectiveness of procedures 
performed. This study was conducted to determine the budget impact of increasing 
the proportion of VATS vs. open lobectomies in a Canadian hospital. Methods: 
We examined the budget impact of increasing the proportion of VATS cases from 
25% to 75%, while decreasing the proportion of open cases by the same amount 
in a hospital that performs 150 lobectomies annually. The model incorporates the 
costs associated with surgery, length of stay (taking into account facility and staff 
costs) and common postoperative complications. The cost data used in the model 
was obtained from peer reviewed literature, the Ontario Case Costing Initiative and 
case costing from a large Canadian hospital. Data on patient outcomes was obtained 
risk of the therapeutic class overall. Methods: A population-based case control 
study was conducted using HealthCore Integrated Research Database (HIRDSM), a 
US commercial insurance claims database. Incident cases of CC were defined as 
patients, ≥ 18 years at diagnosis, with 1st CC diagnostic claim between Jan 1, 2001 to 
Jan 30, 2011. Each case was matched to 1 eligible control based on: no diagnosis of CC 
during study period, actively enrolled at index date of the case, matched to cases by 
length of pre-index enrollment (same or greater), gender & age. Exposure to CV drug 
was defined as at least 1 claim during risk period. Conditional logistic regression was 
used to calculate adjusted Odds Ratios (OR). Sensitivity analysis was conducted where 
minimum CV drug exposure (12 months) was required. Results: 36,736 cases of CC 
were identified in the HIRDSM& successfully matched to controls. Mean age was 60 
years (about 30% were 50-60 years old).Enalapril, labetalol, cholestyramin, diltiazem 
& furosemide (ORs range:1.07-2.05) were positively associated with CC while atorvas-
tatin, pravastatin & simvastatin (ORs range:0.68-0.94) were negatively associated with 
CC. In the sensitivity analyses, positive associations remained for cholestyramine 
& diltiazem, whereas negative associations remained for atorvastatin & simvasta-
tin. ConClusions: These results are consistent with a beneficial impact of statins 
on CC risk. Prolonged use of a small number of CV agents was associated with CC. 
Cholestyramine & diltiazem are associated with increased risk of CC because of the 
condition for which they are prescribed. However, association of individual drugs was 
not consistent with that therapeutic class as a whole. This suggests that cancer risk 
is sometimes drug specific. Grouping drugs into therapeutic classes for studies of 
cancer risk may introduce a bias such that the predominant drug drives the results.
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objeCtives: The U.S. Food and Drug Administration issued a statement indicating 
that pioglitazone, one of the type II diabetes oral hypoglycemic agents, may poten-
tially increase the risk of developing bladder cancer in 2010. This study examined the 
relationship between pioglitazone and incidence rate of bladder cancer among type 
2 diabetes patients in Taiwan by population-based data without financial support 
from any institution. Methods: We analyzed 8 years cohort (2003-2010) in Taiwan 
by using National Health Insurance Database. Approximately 2 million randomly 
sampled representative beneficiaries from the National Health Insurance database 
were used as the data source for analysis. Totally 4,765 patients used pioglitazone 
were followed and compared with 4,765 control cases selected by propensity score 
matched approach. Results: We found that risk of bladder cancer increases with 
age, and risk increased higher for men than women, with a hazard ratio of 1.8. With 
propensity score matching, no significant correlation was found between the risk 
of bladder cancer and pioglitazone using. There was no significant difference in 
survival curves between patients ever used and never used pioglitazone. There is a 
tendency of getting bladder cancer earlier for patients ever used compared to never 
users yet it is not statistically significant. ConClusions: A significant increase 
risk of bladder cancer is observed for patients ever used compared to all diabetes 
patients who never used pioglitazone; however, the risk diminishes after adjust-
ing with propensity score matching. Our study results indicated that the potential 
hazard of pioglitazone might be overestimated.
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objeCtives: While most patients with advanced stages of melanoma generally 
have a poor prognosis, some patients gain long-term benefit from cancer therapy 
and therefore significantly surpass the expected survival time. The goal of the 
study was to investigate whether long-term survivors of advanced melanoma have 
excess mortality risk compared to the general population. Methods: Data per-
taining to 783 patients diagnosed with stage IIIC or IV melanoma during 2003-2011 
were derived from The Netherlands Cancer Registry. The mean age at diagnosis 
was 60.5 years for patients with stage IIIC (n= 414) and 62.1 years with stage IV 
disease (n= 369). Monthly survival rates were derived from the estimated Kaplan-
Meier survival curves for each subgroup for up to 9.6 years of follow-up. Smoothed 
hazard rates were derived from the survival curves. Analysis was conducted to 
determine whether after 5 years of follow-up the 95% confidence interval (CI) of the 
smoothed hazard observed for advanced melanoma patients included that observed 
for a comparable group from the Dutch general population. Results: Median sur-
vival was estimated to be 1.93 years (95%-CI 1.69-2.11) and 0.52 years (0.45-0.62) in 
patients with stage IIIC and IV, respectively. The Kaplan-Meier estimates indicated 
survival rates of 71%, 48%, 33%, 25%, and 21% for stage IIIC and 30%, 20%, 14%, 
10%, and 8% for stage IV melanoma at 1, 2, 3, 5, and 9.6 years respectively. After 
5 years of follow-up the ranges indicated by the 95% CIs of the empirical hazard 
profiles contained that of the general population; the confidence interval ranges 
were small. ConClusions: Relative to the general population, no excess risk was 
found in advanced melanoma patients who survived 5 years and beyond. These 
findings suggest that long-term survival extrapolation approaches should be tested 
for face-validity with general population mortality data.
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